By the numbers: Does circulating tumor cell enumeration have a role in metastatic breast cancer?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A 63-year-old postmenopausal woman was diagnosed with stage II (pT2N0M0), hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer 9 years ago. Her treatment course included breast-conserving local therapy, four cycles of adjuvant chemotherapy with doxorubicin and cyclophosphamide, and 5 years of anastrozole. She developed persistent pain in the left hip 2 years after completing adjuvant endocrine therapy. Radiographic studies identified lesions in the left proximal femur and multiple vertebral bodies consistentwithskeletal metastases.Shestarted fulvestrant in addition tobone-modifyingtherapywithzoledronic acid. After 16 months, a nuclear medicine bone scan indicated likely progression in the bone metastases, prompting a switch to exemestane as second-line endocrine therapy. Six months later, a repeat bone scan identified new findings in the right humerus and scapula. Capecitabine was started as first-line chemotherapy at 1,500mgorally twice per day for 14 days on a 21-day cycle. The patient presents for a routine evaluation after three cycles of capecitabine and reports chronic waxing and waning discomfort in the left hip with weight bearing; left-sided-rib acute pain after she caught her grandson falling off the bed; and progressive dysesthesias, erythema, and capecitabine-related skin thickening and crackingonthe palms and soles.Arestaging bone scan reveals increased radiotracer activity in the left sixth ribandat theknownlesions in the righthumerusandright scapula.Computed tomography scans demonstrate increased focal sclerosis in the right scapula, indicative of either disease progression or treatment response. Plain radiographs identify a subtle fracture of the left sixth rib in the midclavicular line. Serum alkaline phosphatase is borderline increased, and the cancer antigen (CA) 27.29 has fluctuated in the range of 20 to 30U/mLsince she first presented with metastatic disease.Onthe basis of thenewleft rib discomfort and the bothersome toxicity from capecitabine, she inquires whether a change in systemic therapy is indicated.

Original languageEnglish (US)
Pages (from-to)3479-3483
Number of pages5
JournalJournal of Clinical Oncology
Volume32
Issue number31
DOIs
StatePublished - Nov 1 2014

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Scapula
Ribs
Bone and Bones
exemestane
Hip
Therapeutics
Accidental Falls
Neoplasm Metastasis
Paresthesia
Nuclear Medicine
Humerus
Weight-Bearing
Acute Pain
Sclerosis
Erythema
Adjuvant Chemotherapy
Femur
Doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

By the numbers : Does circulating tumor cell enumeration have a role in metastatic breast cancer? / Liu, Minetta C.

In: Journal of Clinical Oncology, Vol. 32, No. 31, 01.11.2014, p. 3479-3483.

Research output: Contribution to journalArticle

@article{ea7da262eeba4578812824618e9effd2,
title = "By the numbers: Does circulating tumor cell enumeration have a role in metastatic breast cancer?",
abstract = "A 63-year-old postmenopausal woman was diagnosed with stage II (pT2N0M0), hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer 9 years ago. Her treatment course included breast-conserving local therapy, four cycles of adjuvant chemotherapy with doxorubicin and cyclophosphamide, and 5 years of anastrozole. She developed persistent pain in the left hip 2 years after completing adjuvant endocrine therapy. Radiographic studies identified lesions in the left proximal femur and multiple vertebral bodies consistentwithskeletal metastases.Shestarted fulvestrant in addition tobone-modifyingtherapywithzoledronic acid. After 16 months, a nuclear medicine bone scan indicated likely progression in the bone metastases, prompting a switch to exemestane as second-line endocrine therapy. Six months later, a repeat bone scan identified new findings in the right humerus and scapula. Capecitabine was started as first-line chemotherapy at 1,500mgorally twice per day for 14 days on a 21-day cycle. The patient presents for a routine evaluation after three cycles of capecitabine and reports chronic waxing and waning discomfort in the left hip with weight bearing; left-sided-rib acute pain after she caught her grandson falling off the bed; and progressive dysesthesias, erythema, and capecitabine-related skin thickening and crackingonthe palms and soles.Arestaging bone scan reveals increased radiotracer activity in the left sixth ribandat theknownlesions in the righthumerusandright scapula.Computed tomography scans demonstrate increased focal sclerosis in the right scapula, indicative of either disease progression or treatment response. Plain radiographs identify a subtle fracture of the left sixth rib in the midclavicular line. Serum alkaline phosphatase is borderline increased, and the cancer antigen (CA) 27.29 has fluctuated in the range of 20 to 30U/mLsince she first presented with metastatic disease.Onthe basis of thenewleft rib discomfort and the bothersome toxicity from capecitabine, she inquires whether a change in systemic therapy is indicated.",
author = "Liu, {Minetta C}",
year = "2014",
month = "11",
day = "1",
doi = "10.1200/JCO.2014.56.6851",
language = "English (US)",
volume = "32",
pages = "3479--3483",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - By the numbers

T2 - Does circulating tumor cell enumeration have a role in metastatic breast cancer?

AU - Liu, Minetta C

PY - 2014/11/1

Y1 - 2014/11/1

N2 - A 63-year-old postmenopausal woman was diagnosed with stage II (pT2N0M0), hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer 9 years ago. Her treatment course included breast-conserving local therapy, four cycles of adjuvant chemotherapy with doxorubicin and cyclophosphamide, and 5 years of anastrozole. She developed persistent pain in the left hip 2 years after completing adjuvant endocrine therapy. Radiographic studies identified lesions in the left proximal femur and multiple vertebral bodies consistentwithskeletal metastases.Shestarted fulvestrant in addition tobone-modifyingtherapywithzoledronic acid. After 16 months, a nuclear medicine bone scan indicated likely progression in the bone metastases, prompting a switch to exemestane as second-line endocrine therapy. Six months later, a repeat bone scan identified new findings in the right humerus and scapula. Capecitabine was started as first-line chemotherapy at 1,500mgorally twice per day for 14 days on a 21-day cycle. The patient presents for a routine evaluation after three cycles of capecitabine and reports chronic waxing and waning discomfort in the left hip with weight bearing; left-sided-rib acute pain after she caught her grandson falling off the bed; and progressive dysesthesias, erythema, and capecitabine-related skin thickening and crackingonthe palms and soles.Arestaging bone scan reveals increased radiotracer activity in the left sixth ribandat theknownlesions in the righthumerusandright scapula.Computed tomography scans demonstrate increased focal sclerosis in the right scapula, indicative of either disease progression or treatment response. Plain radiographs identify a subtle fracture of the left sixth rib in the midclavicular line. Serum alkaline phosphatase is borderline increased, and the cancer antigen (CA) 27.29 has fluctuated in the range of 20 to 30U/mLsince she first presented with metastatic disease.Onthe basis of thenewleft rib discomfort and the bothersome toxicity from capecitabine, she inquires whether a change in systemic therapy is indicated.

AB - A 63-year-old postmenopausal woman was diagnosed with stage II (pT2N0M0), hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer 9 years ago. Her treatment course included breast-conserving local therapy, four cycles of adjuvant chemotherapy with doxorubicin and cyclophosphamide, and 5 years of anastrozole. She developed persistent pain in the left hip 2 years after completing adjuvant endocrine therapy. Radiographic studies identified lesions in the left proximal femur and multiple vertebral bodies consistentwithskeletal metastases.Shestarted fulvestrant in addition tobone-modifyingtherapywithzoledronic acid. After 16 months, a nuclear medicine bone scan indicated likely progression in the bone metastases, prompting a switch to exemestane as second-line endocrine therapy. Six months later, a repeat bone scan identified new findings in the right humerus and scapula. Capecitabine was started as first-line chemotherapy at 1,500mgorally twice per day for 14 days on a 21-day cycle. The patient presents for a routine evaluation after three cycles of capecitabine and reports chronic waxing and waning discomfort in the left hip with weight bearing; left-sided-rib acute pain after she caught her grandson falling off the bed; and progressive dysesthesias, erythema, and capecitabine-related skin thickening and crackingonthe palms and soles.Arestaging bone scan reveals increased radiotracer activity in the left sixth ribandat theknownlesions in the righthumerusandright scapula.Computed tomography scans demonstrate increased focal sclerosis in the right scapula, indicative of either disease progression or treatment response. Plain radiographs identify a subtle fracture of the left sixth rib in the midclavicular line. Serum alkaline phosphatase is borderline increased, and the cancer antigen (CA) 27.29 has fluctuated in the range of 20 to 30U/mLsince she first presented with metastatic disease.Onthe basis of thenewleft rib discomfort and the bothersome toxicity from capecitabine, she inquires whether a change in systemic therapy is indicated.

UR - http://www.scopus.com/inward/record.url?scp=84911478430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911478430&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.56.6851

DO - 10.1200/JCO.2014.56.6851

M3 - Article

C2 - 25245442

AN - SCOPUS:84911478430

VL - 32

SP - 3479

EP - 3483

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -